These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3286439)

  • 1. Randomized, double-blind trial of exifone versus cognitive problems in Parkinson's disease.
    Allain H; Denmat J; Bentue-Ferrer D; Milon D; Pignol P; Reymann JM; Pape D; Sabouraud O; Van den Driessche J
    Fundam Clin Pharmacol; 1988; 2(1):1-12. PubMed ID: 3286439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lecithin treatment of cognitively impaired Parkinson's patients.
    Tweedy JR; Garcia CA
    Eur J Clin Invest; 1982 Feb; 12(1):87-90. PubMed ID: 6802657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1997 Sep; 49(3):665-71. PubMed ID: 9305320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA
    Mov Disord; 2015 Jun; 30(7):1009. PubMed ID: 25880115
    [No Abstract]   [Full Text] [Related]  

  • 8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
    Dupont E; Burgunder JM; Findley LJ; Olsson JE; Dorflinger E
    Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
    Welsh MD; Dorflinger E; Chernik D; Waters C
    Mov Disord; 2000 May; 15(3):497-502. PubMed ID: 10830415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.
    Grace J; Amick MM; Friedman JH
    J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):18-23. PubMed ID: 18931006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC; Jamieson CF; Donaldson IM
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
    Doraiswamy PM; Babyak MA; Hennig T; Trivedi R; White WD; Mathew JP; Newman MF; Blumenthal JA
    Psychopharmacol Bull; 2007; 40(2):54-62. PubMed ID: 17514186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind evaluation of ciladopa in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
    Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.